[go: up one dir, main page]

IN2014DN09445A - - Google Patents

Info

Publication number
IN2014DN09445A
IN2014DN09445A IN9445DEN2014A IN2014DN09445A IN 2014DN09445 A IN2014DN09445 A IN 2014DN09445A IN 9445DEN2014 A IN9445DEN2014 A IN 9445DEN2014A IN 2014DN09445 A IN2014DN09445 A IN 2014DN09445A
Authority
IN
India
Prior art keywords
protein complexes
viral proteins
engineered viral
vaccine
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Christopher Patrick Marshall
Original Assignee
Marshall Christophe R Patrick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marshall Christophe R Patrick filed Critical Marshall Christophe R Patrick
Publication of IN2014DN09445A publication Critical patent/IN2014DN09445A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • G01N33/56988HIV or HTLV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
IN9445DEN2014 2012-05-09 2013-05-09 IN2014DN09445A (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644830P 2012-05-09 2012-05-09
PCT/US2013/040228 WO2013169961A1 (en) 2012-05-09 2013-05-09 Conformationally specific viral immunogens

Publications (1)

Publication Number Publication Date
IN2014DN09445A true IN2014DN09445A (ar) 2015-07-17

Family

ID=49548782

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9445DEN2014 IN2014DN09445A (ar) 2012-05-09 2013-05-09

Country Status (7)

Country Link
US (6) US20130302366A1 (ar)
EP (2) EP3483174A1 (ar)
JP (4) JP2015518819A (ar)
AU (5) AU2013259548A1 (ar)
CA (1) CA2873048C (ar)
IN (1) IN2014DN09445A (ar)
WO (1) WO2013169961A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773309T3 (es) 2013-07-25 2020-07-10 Calder Biosciences Inc Proteínas F de pre-fusión de VRS estabilizadas conformacionalmente
WO2015020913A2 (en) 2013-08-03 2015-02-12 Marshall Christopher Patrick Influenza hemagglutinin proteins and methods of thereof
WO2019032480A1 (en) 2017-08-07 2019-02-14 Avatar Medical, Llc PROTEINS F PRE-FUSION OF RSV STABILIZED IN TERMS OF CONFORMATION
US11623004B2 (en) 2018-03-16 2023-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncytial virus infection
MX2022014224A (es) * 2020-05-12 2023-02-23 Univ California Construcciones de anticuerpos de dominio individual neutralizantes contra sars-cov2.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311920B1 (en) * 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US6534064B1 (en) 1999-10-13 2003-03-18 Chiron Corporation Stabilized protein particles for inducing cellular immune responses
WO2001029247A1 (en) * 1999-10-15 2001-04-26 Avatar Medical, Llc Stabilized proteins
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7179468B1 (en) * 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
WO2003052122A2 (en) 2001-12-17 2003-06-26 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Gp41 inhibitor
WO2004069863A2 (en) 2003-02-04 2004-08-19 New York University Constrained hiv v3 loop peptides as immunogens and receptor antagonists
US20050054572A1 (en) * 2003-07-03 2005-03-10 Marshall Christopher P. Methods for obtaining molecules with reduced immunogenicity
AU2005250430B2 (en) * 2004-06-01 2011-10-13 Msd Italia S.R.L. Stable peptide mimetic of HIV gp41 fusion intermediate
WO2007149491A2 (en) * 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Soluble stabilized trimeric hiv env proteins and uses thereof
WO2009015842A2 (en) * 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
US20090246191A1 (en) * 2007-10-11 2009-10-01 University Of Tennessee Research Foundation Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof
SMT202000101T1 (it) * 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
WO2011066221A1 (en) 2009-11-24 2011-06-03 International Aids Vaccine Initiative Immunogen prioritization for vaccine design
WO2011146120A2 (en) 2010-05-18 2011-11-24 Marshall Christopher P Assay for identifying antigens that activate b cell receptors comprising neutralizing antibodies
WO2013063366A2 (en) * 2011-10-27 2013-05-02 Stc.Unm Methods for screening viral like particles and identifying neutralizing epitopes and related vaccines, constructs, and libraries
WO2013107290A1 (en) 2012-01-20 2013-07-25 The Government of the Hong Kong Special Administrative Region of the People's Republic of China A novel paramyxovirus and uses thereof

Also Published As

Publication number Publication date
US11752191B2 (en) 2023-09-12
JP7472209B2 (ja) 2024-04-22
EP2846828B1 (en) 2018-11-21
JP2022163180A (ja) 2022-10-25
US20240238369A1 (en) 2024-07-18
US20210322512A1 (en) 2021-10-21
AU2018200502B2 (en) 2019-10-03
AU2019216695A1 (en) 2019-09-05
CA2873048C (en) 2020-10-27
US20190105368A1 (en) 2019-04-11
AU2021204169B2 (en) 2023-11-23
EP3483174A1 (en) 2019-05-15
WO2013169961A1 (en) 2013-11-14
JP6692853B2 (ja) 2020-05-13
EP2846828A1 (en) 2015-03-18
US20130302366A1 (en) 2013-11-14
AU2018200502A1 (en) 2018-02-15
AU2021204169A1 (en) 2021-07-15
CA2873048A1 (en) 2013-11-14
US10155023B2 (en) 2018-12-18
AU2024201200A1 (en) 2024-03-14
JP2015518819A (ja) 2015-07-06
JP2018150330A (ja) 2018-09-27
AU2013259548A1 (en) 2014-11-27
EP2846828A4 (en) 2015-07-01
JP2020125323A (ja) 2020-08-20
US20180117116A1 (en) 2018-05-03
US20130317205A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2024010676A (es) Metodos para mejorar la eficacia de una vacuna mediante el uso de un antagonista il-4r.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
MX2015013235A (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
WO2013054199A3 (en) Cmv antigens and uses thereof
EA202090699A2 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
EA201391515A1 (ru) Инактивированная вакцина вируса денге
WO2015052543A3 (en) Malaria vaccination
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
ZA202204981B (en) Synthetic chimeric poxviruses
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
TN2018000180A1 (en) Polypeptides inhibiting cd40l
IN2014DN09445A (ar)
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2017008406A (es) Conjugados de aminoacidos y peptidos y sus usos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX363149B (es) Vacunas de nucleoproteina de la influenza.
WO2016049522A3 (en) Compositions comprising ch505 envelopes, and trimers
MX2019007924A (es) Vacunas contra la influenza.
WO2015086354A3 (en) Novel promiscuous hpv16-derived t helper epitopes for immunotherapy
MX358507B (es) Antigenos vacunales quimericos contra el virus de la hepatitis c.